University of California

Neotope Biosciences Limited

Elan Pharmaceuticals, Inc.

Prothena Biosciences Limited

Manuel J Buttini

Dale Bernard Schenk

Tamie Chilcote

Edward Rockenstein

Kate Dora Games

Eliezar Masliah

Eliezer Masliah

Lennart Mucke

Robert W Mahley

Jacob Raber

Robert E Pitas

Tamie J Chilcote

Dora Kate Games

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Treatment and delay of outset of synucleinopathic and amyloidogenic disease

Prevention and treatment of synucleinopathic and amyloidogenic disease

Treatment and delay of onset of synucleinopathic and amyloidogenic disease

The present invention features non-human transgenic animal models for gene function, wherein the transgenic animal is characterized by having altered endogenous apolipoprotein E gene function and a transgene for an exogenous human apolipoprotein E isoform. The transgenic animals may be either homozygous or heterozygous for the transgene. The invention also features methods for using non-human transgenic animal models for the study of apolipoprotein E-mediated pathologies and the identification of compounds and therapies for such pathologies.

Apolipoprotein E transgenic mice and assay methods

Growing community of inventors

Emeryville, CA, United States of America

Manuel J Buttini